Paper Details

  1. Home
  2. Paper Details

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.

Author: BedfordP, BrownD, ChatfieldS, DouganG, EdelmanR, KotloffK L, LevineM M, LosonskyG, NataroJ P, PerryJ, SzteinM B, TacketC O, WassermanS S, WyantT L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

CVD 908-htrA, a live attenuated Salmonella Typhi strain, is a promising new oral vaccine for typhoid fever. The vaccine was well-tolerated and elicited a strong immune response.
Paper Details　
Original Abstract of the Article :
Salmonella enterica serovar Typhi strain CVD 908-htrA is a live attenuated strain which may be useful as an improved oral typhoid vaccine and as a vector for cloned genes of other pathogens. We conducted a phase 2 trial in which 80 healthy adults received one of two dosage levels of CVD 908-htrA in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1128/IAI.68.3.1196-1201.2000

データ提供：米国国立医学図書館（NLM）

A New Oasis in the Desert of Typhoid Fever: A Phase 2 Trial

Typhoid fever, a serious bacterial infection, is a formidable foe, a desert storm that can quickly overwhelm the body. This study explores the potential of a novel typhoid vaccine, CVD 908-htrA, a live attenuated strain of Salmonella enterica serovar Typhi. It's like searching for a new oasis in a vast desert, seeking a more effective way to protect against this debilitating disease.

The researchers conducted a phase 2 trial, evaluating the safety and immunogenicity of CVD 908-htrA in healthy adults. They investigated two different dosage levels of the vaccine, comparing their effectiveness to a placebo. It's like studying the impact of different irrigation techniques on a desert oasis, testing different approaches to ensure optimal growth and resilience.

A Promising Oasis in the Fight Against Typhoid Fever

The study found that the vaccine was well-tolerated and induced immune responses in a significant proportion of participants, suggesting its potential as a single-dose vaccine against typhoid fever. It's like discovering a sustainable and reliable source of water in a desert, offering a promising solution to a persistent threat.

A Beacon of Hope for Typhoid Prevention

This study provides encouraging evidence for the potential of CVD 908-htrA as an effective typhoid vaccine. It's a beacon of hope in the desert of typhoid fever, offering a potential way to protect individuals and communities from this serious infection.

Dr. Camel's Conclusion

This phase 2 trial offers promising results for the development of CVD 908-htrA as a single-dose typhoid vaccine. It's a testament to the power of scientific innovation to find new oases of protection in the desert of infectious diseases.

Date :
  1. Date Completed 2000-03-16
  2. Date Revised 2021-05-26
Further Info :

Pubmed ID

10678926

DOI: Digital Object Identifier

10.1128/IAI.68.3.1196-1201.2000

Related Literature

Article Analysis
・Side Effects of typhoid vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.